What is the current stock price of 89bio, Inc. (ETNB)?

As of the latest market data, 89bio, Inc. (ETNB) is trading at $14.84. The stock has seen a loss of 0.00% today.

Does 89bio, Inc. (ETNB) pay a dividend?

Based on current data, 89bio, Inc. does not have a confirmed active dividend policy.

What is the market cap of 89bio, Inc.?

The current market capitalization of 89bio, Inc. (ETNB) is approximately unavailable.

ETNB

89bio, Inc.·Healthcare

14.84

0.000%(+0.00)

Market Closed

14.97

0.876%(+0.13)

After Hours

Last Updated: — ET

52W L: $4.1652W H: $15.06

Company Profile

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-11-11

Beta

1.26

Websitewww.89bio.com↗